Form 4: Avidity Director Sells Shares in Novartis Merger

Avidity Biosciences Director Troy Edward Wilson disposed of all his common stock and stock options as part of the previously announced merger with Novartis at $72.00 per share.

Summary

• Director Troy Edward Wilson reported the disposition of Avidity Biosciences, Inc. (RNAM) securities.
• The transactions occurred on February 27, 2026, pursuant to the Agreement and Plan of Merger with Novartis AG, dated October 25, 2025.
• Wilson disposed of 65,091 shares of common stock held directly and 13,711 shares held indirectly through a family trust.
• He also disposed of stock options totaling 38,523 shares, comprising 10,034 options (exercise price $33.62), 13,489 options (exercise price $39.96), and 15,000 options (exercise price $26.09).
• The stock options were exchanged for a cash payment equal to the merger consideration of $72.00 per share, minus their respective exercise prices.
• Following these transactions, Wilson's beneficial ownership of the reported securities is zero.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as a procedural report confirming the execution of a previously announced merger, which is generally positive for shareholders receiving a premium but signifies the end of the independent company.

Positives

• The merger consideration of $72.00 per share for stock options indicates a premium over the exercise prices ($33.62, $39.96, $26.09), resulting in a cash payout for option holders.
• The completion of the merger provides liquidity and a defined exit for shareholders and option holders.

Negatives

• The disposition of all reported securities by a director indicates the cessation of their ownership stake in the company, typically following an acquisition.
• Shareholders will no longer participate in the future growth or potential upside of Avidity Biosciences as an independent entity.

Future Outlook

The filing indicates the completion of the merger with Novartis AG, suggesting Avidity Biosciences, Inc. will no longer operate as an independent publicly traded entity. The future outlook for the former Avidity Biosciences assets and operations will be integrated into Novartis's strategic plans.

Industry Context

StockSavvy.ai notes that this transaction reflects the ongoing consolidation trend within the biotechnology and pharmaceutical sectors, where larger pharmaceutical companies acquire innovative smaller biotechs to bolster their pipelines and intellectual property. The acquisition of Avidity Biosciences by Novartis aligns with strategies to gain access to novel therapeutic platforms, such as Avidity's AOC platform.

Comparison to Industry Standards

• The $72.00 per share merger consideration can be compared to recent biotech acquisitions, such as Pfizer's acquisition of Seagen for $43 billion ($229 per share) or AbbVie's acquisition of ImmunoGen for $10.1 billion ($31.26 per share).
• The structure of the option payout (cash for in-the-money options) is standard practice in M&A transactions.

Stakeholder Impact

• Shareholders: Received cash consideration for their shares, providing liquidity and a defined return on investment.
• Employees: Future employment and integration into Novartis AG's structure.
• Management: Director Troy Edward Wilson disposed of his equity, indicating the conclusion of his beneficial ownership stake in the independent Avidity.

Next Steps

• Integration of Avidity Biosciences' operations and assets into Novartis AG.
• Avidity Biosciences, Inc. will cease to be a publicly traded company.

Key Dates

Keywords

Avidity Biosciences, RNAM, Novartis, Merger, Acquisition, Form 4, Insider Transaction, Stock Options, Common Stock, Troy Edward Wilson